Pediatric Phase I Trial and Pharmacokinetic Study of Dasatinib: A Report From the Children's Oncology Group Phase I Consortium

PURPOSE: Dasatinib is an orally available tyrosine kinase inhibitor with low nanomolar activity against SRC family kinases, BCR-ABL, c-KIT, EPHA2, and the PDGF-β receptor. Dasatinib was found to have selective activity in several tumor models in the Pediatric Preclinical Testing Program. PATIENTS AN...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Aplenc, Richard, Blaney, Susan M., Strauss, Lewis C., Balis, Frank M., Shusterman, Suzanne, Ingle, Ashish Mark, Agrawal, Shruti, Sun, Junfeng, Wright, John J., Adamson, Peter C.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2011
Soggetti:
Original Reports
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3068059/
https://ncbi.nlm.nih.gov/pubmed/21263099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.30.7231
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi